UNSPSC 51311610: Nedocromil sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H15NO7.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ET8IF4KS1T, chemically known as 4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt but more generally known as nedocromil sodium, which bears US NIH Compound Identifier 50295. European Medicines Agency schedules Nedocromil sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14634MIG.

UNSPSC 51311610 Nedocromil sodium is a Commodity code that nominally covers a specific asthma-control pharmaceutical, yet recent state and local procurement activity under this code shows little alignment with that product. The three recent opportunities posted in the source—a Seminole County IFB for naloxone and drug deactivation systems, a Texas HHS RFI for direct-to-manufacturer prescription program capabilities, and a Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products—reflect broader pharmaceutical procurement and supply-chain management activity rather than nedocromil sodium in particular. State and local health departments, cooperative purchasing alliances, and county health agencies appear to be the primary issuing bodies soliciting under this code tier, driven by community health initiatives, pharmacy benefit management, and wholesale distribution partnerships.

The geographic spread of recent activity spans Florida, Texas, and Minnesota through cooperative purchasing vehicles and individual county health authorities. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual quantities of naloxone and drug deactivation systems with a July 26, 2023 response deadline and quarterly delivery cycles. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP cooperative, posted in January 2026 with a March 26, 2026 deadline, sought generic pharmaceutical and OTC product manufacturers to supply through three authorized wholesalers, with contracts effective July 1, 2026. The code shows little recent activity specifically targeting nedocromil sodium, suggesting either a mismatch between the code assignment and actual procurement scope or minimal demand for this particular pharmaceutical in state and local procurement channels.